Bundelkhand Online Journal

Pulmonary Arterial Hypertension (PAH) Clinical and Commercial Assessment of the Pipeline Therapies, Market Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Pulmonary Arterial Hypertension (PAH) Clinical and Commercial Assessment of the Pipeline Therapies, Market Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

July 16
03:42 2021
Pulmonary Arterial Hypertension (PAH) Clinical and Commercial Assessment of the Pipeline Therapies, Market Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Pulmonary Arterial Hypertension (PAH) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension (PAH) Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension that is characterized by elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.

The main purpose of the treatment of Pulmonary Arterial Hypertension is to improve the symptoms of patients and slowing the rate of clinical deterioration. General measures, supportive therapy, pharmacological treatment, and Surgical Treatment are used for treating Pulmonary Arterial Hypertension (PAH). Oral anticoagulants, supplemental oxygen therapy, and cardiovascular drugs are used as supportive therapy for treating Pulmonary Arterial Hypertension.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market

The Pulmonary Arterial Hypertension (PAH) Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Pulmonary Arterial Hypertension (PAH) market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Pulmonary Arterial Hypertension (PAH) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Pulmonary Arterial Hypertension (PAH) Market

Pulmonary Arterial Hypertension (PAH) Market Key Facts

  • PAH is a rare disorder found in 15 to 50 persons per million within the United States and Europe. Idiopathic, heritable, and anorexigen-induced PAH make up 52.6% of all PAH cases. Generally, PAH affects women aged between 30 and 60 years. However, it can occur in males and is often associated with worse clinical outcomes. 

  • According to DelveInsight’s analysis, females have a high prevalence of PAH as compared to males.

  • As per the study conducted by Kirson et.al. (2011), the prevalence of Pulmonary Arterial Hypertension was observed to be 109 per million individuals (PMI) among the population of fewer than 65 years old. Prevalence of Pulmonary Arterial Hypertension was found to be 451 per million individuals (PMI) among age groups older than 65 years.

Key Benefits of Pulmonary Arterial Hypertension (PAH) Market Report

  • Pulmonary Arterial Hypertension (PAH) market report provides an in-depth analysis of Pulmonary Arterial Hypertension (PAH) Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Pulmonary Arterial Hypertension (PAH) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Pulmonary Arterial Hypertension (PAH) current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Pulmonary Arterial Hypertension (PAH) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Pulmonary Arterial Hypertension (PAH) Market 

The market size of Pulmonary Arterial Hypertension (PAH) is anticipated to increase during the study period owing to the increasing incident population of PAH patients in the 7MM. Extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies will also fuel the growth of the market.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Pulmonary Arterial Hypertension (PAH) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Pulmonary Arterial Hypertension (PAH) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Pulmonary Arterial Hypertension (PAH) Epidemiology

The epidemiology section covers insights about the historical and current Pulmonary Arterial Hypertension (PAH) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Pulmonary Arterial Hypertension (PAH) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension (PAH) market or expected to get launched in the market during the study period. The analysis covers Pulmonary Arterial Hypertension (PAH) market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Pulmonary Arterial Hypertension (PAH) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Pulmonary Arterial Hypertension (PAH) market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Pulmonary Arterial Hypertension (PAH) emerging therapies.

Request for Sample @ Pulmonary Arterial Hypertension (PAH) Therapeutics Market Assessment

An increase in the growth of the market is expected due to upcoming therapies for the treatment of PAH which is expected to create a positive impact during the forecast period.

Key Companies in the Pulmonary Arterial Hypertension (PAH) Market:

  • United Therapeutics Corp.

  • Arena Pharmaceuticals

  • Altavant Sciences

  • Acceleron Pharma

  • Reata Pharmaceuticals

  • Liquidia Technologies

  • PhaseBio Pharmaceuticals

  • Complexa

And many others.

Pulmonary Arterial Hypertension (PAH) Therapies covered in the report includes:

  • CXA-10

  • Aurora-GT

  • Ralinepag

  • RVT-1201

  • Sotatercept 

  • PB1046 Injection

  • Bardoxolone methyl 

  • Inhaled dry powder treprostinil 

And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Pulmonary Arterial Hypertension (PAH) Competitive Intelligence Analysis

4. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance

5. Pulmonary Arterial Hypertension (PAH) Disease Background and Overview

6. Pulmonary Arterial Hypertension (PAH) Patient Journey

7. Pulmonary Arterial Hypertension (PAH) Epidemiology and Patient Population

8. Pulmonary Arterial Hypertension (PAH) Treatment Algorithm, Current Treatment, and Medical Practices

9. Pulmonary Arterial Hypertension (PAH) Unmet Needs

10. Key Endpoints of Pulmonary Arterial Hypertension (PAH) Treatment

11. Pulmonary Arterial Hypertension (PAH) Marketed Products

12. Pulmonary Arterial Hypertension (PAH) Emerging Therapies

13. Pulmonary Arterial Hypertension (PAH) Seven Major Market Analysis

14. Attribute Analysis

15. Pulmonary Arterial Hypertension (PAH) Market Outlook (7 major markets)

16. Pulmonary Arterial Hypertension (PAH) Access and Reimbursement Overview

17. KOL Views on the Pulmonary Arterial Hypertension (PAH) Market.

18. Pulmonary Arterial Hypertension (PAH) Market Drivers

19. Pulmonary Arterial Hypertension (PAH) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market

Latest Reports By DelveInsight

Pulmonary Arterial Hypertension Pipeline Insights
Pulmonary Arterial Hypertension Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Pulmonary Arterial Hypertension (PAH) Market.

Neuromodulation Devices Market Insights

DelveInsight’s ‘Neuromodulation Devices -Market Insights, Competitive Landscape, and Market Forecast – 2026’ report delivers an in-depth understanding of Neuromodulation Devices and the historical and forecasted Neuromodulation Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/capitalnews/bundelkhandonlinejournal.in/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Categories